• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

    13.04 +1.47 (+12.76%)
    Streaming Delayed Price Updated: 10:58 AM EDT, Apr 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MiNK Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
    Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
    Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
    iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
    New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
    Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
    Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
    From MiNK Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.